Zhejiang Jingxin Pharmaceutical Hits Day High with 4.49% Surge

Zhejiang Jingxin Pharmaceutical Co., Ltd. has experienced a notable increase of 4.49% on March 10, 2026, reaching an intraday high of CNY 16.30. This performance stands out against the backdrop of the China Shanghai Composite, which only rose by 0.65% on the same day. Over the past week, Zhejiang Jingxin has shown a solid gain of 3.08%, while its one-month performance reflects a decline of 5.59%. Despite this recent uptick, the stock has faced challenges year-to-date, with a decrease of 15.44%, contrasting with the Shanghai Composite's positive performance of 3.89%. In terms of financial metrics, the company boasts a market capitalization of CNY 12,025 million and a price-to-earnings ratio of 23.00. The return on equity stands at 13.37%, indicating a fair valuation with a price-to-book ratio of 2.13. Additionally, the stock offers a dividend yield of 1.91%. While the company has shown resilience in the short term, its long-term growth metrics, including net sales growth of 3.99% over the last five years, suggest a cautious outlook.